GeoVax Labs, Inc. has announced an update to its Scientific Advisory Board, welcoming four internationally recognized experts whose work spans vaccine design, T-cell immunology, viral pathogenesis, and immunocompromised-host medicine. This strategic expansion is designed to support GeoVax's development efforts with its multi-antigen MVA vector platform for vaccines targeting biothreat pathogens and vulnerable populations such as those from low- and middle-income countries and immunocompromised patients.
The newly appointed members join Prof. Teresa Lambe, whose appointment was previously announced. Dr. Alessandro Sette, an authority in T-cell epitope mapping and immune correlates of protection, leads the NIH Immune Epitope Database and is recognized for defining T-cell immunity across SARS-CoV-2, Mpox, and Ebola. Prof. Lance Turtle specializes in viral pathogenesis and post-infection immune recovery, providing translational insights into long-term immunity and emerging pathogen preparedness. Prof. Thushan I. de Silva is an expert in human viral immunology, vaccine responses, and global immunosurveillance, leading studies across Europe, Asia, and Africa evaluating population-level vaccine immunity and viral evolution. Dr. Joshua A. Hill focuses on vaccine response in immunocompromised and transplant patients, aligning with GeoVax's emphasis on protecting high-risk, underserved populations.
David Dodd, GeoVax Chairman & CEO, stated that assembling this exceptional team strengthens GeoVax's position at the forefront of vaccine innovation. Their combined experience from antigen design to human immunology and clinical translation aligns with the company's mission to deliver durable, broad-spectrum protection to both global and immunocompromised populations. Dr. Kelly McKee, Chief Medical Officer, added that the addition ensures clinical strategy is guided by cutting-edge immunology insight and global research expertise, with collaboration instrumental as GeoVax advances vaccines and immunotherapies designed to protect vulnerable populations.
Dr. Mark Newman, Chief Scientific Officer, noted that this expanded SAB strengthens multiple aspects of the company's R&D platform, ensuring vaccine and immunotherapy candidates deliver real-world impact with input from respected scientific leaders. The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients, a booster vaccine in patients with chronic lymphocytic leukemia, and a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines. For more information about the current status of clinical trials and other updates, visit https://www.geovax.com.
This development matters to business and technology leaders because it signals GeoVax's commitment to addressing significant global health challenges through advanced vaccine technology. The inclusion of experts with specific focus on underserved populations and immunocompromised patients indicates a strategic move toward filling critical gaps in current vaccine coverage, potentially creating new market opportunities while addressing public health needs. The emphasis on T-cell science and multi-antigen platforms suggests innovation in vaccine durability and breadth of protection, which could have implications for pandemic preparedness and biodefense strategies. For investors and industry observers, this strengthened advisory board enhances GeoVax's credibility in advancing complex vaccine candidates through clinical development, particularly for populations that have been underserved by traditional approaches.
